JAK3 and malignant glioma: However, the ability of RXFP1 to engage the JAK3‐STAT3 signaling pathway provides a hitherto underappreciated new route of promoting GBM invasiveness and, in part, may explain the limited treatment success of JAK2 inhibitors in malignant glioma.